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Abstract
Whether exhaled NO helps to identify a specific phenotype of asthmatic patients remains debated. Our aims were
to evaluate whether exhaled NO (FENO0.05) is independently associated (1) with underlying pathophysiological
characteristics of asthma such as airway tone (bronchodilator response) and airway inflammation (inhaled
corticosteroid [ICS]-dependant inflammation), and (2) with clinical phenotypes of asthma.
We performed multivariate (exhaled NO as dependent variable) and k-means cluster analyses in a population of
169 asthmatic children (age ± SD: 10.5 ± 2.6 years) recruited in a monocenter cohort that was characterized in a
cross-sectional design using 28 parameters describing potentially different asthma domains: atopy, environment
(tobacco), control, exacerbations, treatment (inhaled corticosteroid and long-acting bronchodilator agonist), and
lung function (airway architecture and tone).
Two subject-related characteristics (height and atopy) and two disease-related characteristics (bronchodilator
response and ICS dose > 200 μg/d) explained 36% of exhaled NO variance. Nine domains were isolated using
principal component analysis. Four clusters were further identified: cluster 1 (47%): boys, unexposed to tobacco,
with well-controlled asthma; cluster 2 (26%): girls, unexposed to tobacco, with well-controlled asthma; cluster 3
(6%): girls or boys, unexposed to tobacco, with uncontrolled asthma associated with increased airway tone, and
cluster 4 (21%): girls or boys, exposed to parental smoking, with small airway to lung size ratio and uncontrolled
asthma. FENO0.05 was not different in these four clusters.
In conclusion, FENO0.05 is independently linked to two pathophysiological characteristics of asthma (ICS-dependant
inflammation and bronchomotor tone) but does not help to identify a clinically relevant phenotype of asthmatic
children.
Introduction
Numerous studies have evaluated exhaled nitric oxide
(NO) correlates in asthma. For instance, exhaled NO
fraction (FENO) has been linked to atopy rather than to
asthma per se which could be due to the underlying
relationship between FENO and eosinophilic inflamma-
tion of airways[1]. We and others have emphasized that
FENO is also linked to other intrinsic dimensions of
asthma such as airway reactivity/tone [2,3] and remodel-
ing of airways[1,4]. All these relationships may explain
the complex and still debated relationship between
exhaled NO and asthma control/severity[4-6]. Moreover,
extrinsic factors also affect FENO such as tobacco expo-
sure and asthma treatment[6,7]. Finally, the epithelial
surface of airways, which is linked to the height of the
subject and possibly to sex, also affects exhaled NO[8].
Despite this considerable background, the usefulness of
its assessment in clinical practice remains debated
because of its multidimensional nature, precisely.
Furthermore, all these intrinsic and extrinsic exhaled
NO modifiers seem to contribute for a minor part of
exhaled NO variance,[6] which constitutes a main
limitation.
The recent study of Dweik and colleagues has shown
that FENO may define an asthma phenotype. They demon-
s t r a t e dt h a tt h e i rh i g hF E NO phenotype (FENO 0.05 >3 5
ppb) was characterized by greatest airway reactivity, air-
flow limitation, hyperinflation, sputum eosinophilia and
levels of symptoms[9]. Nevertheless, FENO levels were
similar among patients with severe and non-severe asthma
in this latter study. One may hypothesize that the estab-
lishment of one or several relationships between FENO and
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not sufficient to demonstrate that exhaled NO identifies a
specific phenotype with clinical relevance, accordingly to a
more focused definition of phenotype[10].
T h ea i m so fo u rs t u d yw e r et h e r e f o r e( 1 )t oe v a l u a t e
the strength of the relationships between exhaled NO
and physiopathological asthma characteristics, and (2) to
assess whether a specific clinical phenotype can be iso-
lated using exhaled NO measurement. For that purpose,
we used two different statistical approaches. The first
approach determined the clinical and physiological
correlates of exhaled NO, and the degree of FENO var-
iance explained by the correlates. The second approach
used a more complex statistical tool, namely cluster
analysis, which describes the dimensions of disease with-
out the need for arbitrary ap r i o r iassumptions about
classification, and was specifically designed to test the
hypothesis that FENO is associated with a phenotype of
childhood asthma.
Methods
Design of the study
La Berma Cohort
This single centre cohort conducted in a secondary care
out-hospital clinic enrolls asthmatic children since 1997.
Since 2008, exhaled NO and clinical events were
recorded. Levels of asthma control were systematically
assessed using only two levels of GINA guidelines dur-
ing past three months:[11] controlled versus partially/
uncontrolled asthma (omitting lung function since PFT
were obtained without treatment). Severe exacerbations,
according to ATS/ERS definition, [12] and the number
of days (1) with symptoms (GINA guidelines) [11] and
(2) with systemic steroid were specifically recorded. This
cohort has been declared to our regulatory agency
for computer data collection (Commission Nationale
Informatique et Libertés, n°1408710), and approval from
the Ethics Committee of French learned Society of
Pulmonology - SPLF was obtained (CEPRO 2009/019). All
children and parents were informed of the prospective
recording of clinical and physiological data.
Patients and criteria of selection from the cohort
We selected a sample of children, meeting the criteria of
clinical (episodic symptoms of airflow obstruction with
excluded alternative diagnoses) and functional (docu-
mented bronchodilator response based on FEV1 or
sRaw)[13] diagnosis of asthma and who satisfied a full
description of their asthma: these 28 variables (see
Table 1) are categorized as (1) anthropometrics, (2) past
history, (3) parental smoking (more than 5 cigarettes
per day), level of control, treatment, and (3) pulmonary
function. All data were those specifically determined
at the time of only one visit, corresponding to routine eva-
luation in France. These variables allowed the assessment
of three domains of asthma severity: level of current
prescribed treatment, level of current baseline control of
asthma and immediate past burden of asthma exacerba-
tions, accordingly to Bush and Saglani[14]. The population
included in the current retrospective, post hoc, database
design study overlaps to some extent with the populations
of children published previously[2,6,15-17].
Table 1 Clinical and physiological characteristics
of the asthmatic children
Characteristics N = 169
Sex (male, %) 104 (61%)
age, years 10.5 ± 2.6
height, cm 142 ± 15
weight, kg 38 ± 15
BMI, kg.m
-2 18.0 ± 3.5
Atopic status (skin prick test)
negative 27 (16%)
1 positive 41 (24%)
> 1 positive 101 (60%)
Tobacco exposure, n (%)
maternal 25 (15%)
paternal 24 (14%)
paternal and maternal 36 (21%)
Clinical events within past 3 months
controlled, n (%) 56 (33%)
partially or uncontrolled 113 (67%)
number of days with symptoms, median [IQ] 4 [0-12]
severe exacerbation 42 (31%)
number of days with systemic steroid, median
[IQ]
0 [0-2]
Treatment
beta-agonist on demand, n (%) 82 (48%)
low ICS dose, n (%); mean ± SD dose, μg 45 (27%); 154 ± 51
medium ICS dose, n (%); mean ± SD dose, μg 28 (17%); 357 ± 50
high ICS dose, n (%); mean ± SD dose, μg 14 (8%); 707 ± 154
LABA, n (%) 73 (43%)
Pulmonary function tests Pre BD Post BD
sRaw, % predicted 204 ± 45 126 ± 30
FEV1, % predicted 97 ± 13 107 ± 12
FEV1/FVC, % 78 ± 8 84 ± 6
FVC, % predicted 105 ± 13 108 ± 12
FEF75-25%, % predicted 71 ± 19 91 ± 20
FEF50%, % predicted 71 ± 18 91 ± 19
TLC, % predicted 104 ± 11 103 ± 10
FRC, % predicted 103 ± 17 100 ± 15
RV, % predicted 107 ± 28 93 ± 22
RV/TLC 0.25 ±
0.06
0.22 ±
0.05
FEF50%/TLC 0.71 ±
0.14
0.80 ±
0.18
FENO0.05 ppb, median [IQ] 29 [15-48]
BD: denotes bronchodilator
Results are provided as mean ± SD or median [25
th – 75
th percentiles: IQ]
or absolute number with percent age (%).
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Exhaled NO was measured online, using the Nitric
Oxide Analyzer (NIOX; Aerocrine AB; Solna, Sweden:
measurement at a constant 50 mL/s expiratory flow
rate: FENO,0.05). Measurements were performed accord-
ing to the ERS/ATS guidelines before pulmonary func-
tion tests[18].
Pulmonary function tests (PFT)
All PFT were performed without inhaled treatment
(bronchodilator or LABA/ICS association) on the day of
the measurement, by the same operator (BM). Spirome-
try and plethysmographic measurement of specific air-
way resistance and thoracic gas volume were performed
according to international guidelines and as previously
described[13,15,19]. The bronchodilator response to sal-
butamol 400 μg: (post minus baseline)/baseline FEV1
was systematically assessed. Reference values were based
on equations edited by Zapletal,[20] as commonly done
in Europe[21].
Statistical analysis
First approach
Potential explanatory variable were: age, gender, height,
atopy, tobacco exposure, control, treatment and
pulmonary function tests. The association between the
different explanatory variables and FENO was examined
in a multiple linear regression model using the proce-
dure for general linear models with log-transformed
FENO values as the dependent variable. The multivariate
analysis was performed with a backward selection
method and variables with P values of less than 0.05
were retained in the FENO model.
Second approach
We used the same approach than Haldar and colleagues
[22]. Briefly, a cluster analysis methodology was applied
to define homogeneous groups of patients. Principal
component analysis (PCA) is a mathematical procedure
that uses an orthogonal transformation to convert a set
of observations of possibly correlated variables into a set
of values of uncorrelated variables called principal com-
ponents. The number of principal components is usually
less than the number of original variables (data reduc-
tion). To obtain reliable results, the minimal number of
subjects providing usable data for the analysis should be
five times the number of variables being analyzed (28 ×
5 = 140). This transformation is defined in such a way
that the first principal component has as high a variance
as possible, and each succeeding component in turn has
the highest variance possible under the constraint that it
be orthogonal to (uncorrelated with) the preceding com-
ponents. Then we requested a rotation of the resulting
factors which follows completion of the analysis of the
d a t a [ 2 3 ] .I th a sb e e ns h o w nt h a tt h er e l a x e ds o l u t i o no f
k-means clustering, a common method of cluster analy-
sis,[24] specified by the cluster indicators, is given by
the PCA principal components, and thus PCA facilitates
k-means clustering to find near-optimal solutions[25].
Cluster analysis allows the partitioning of data into
meaningful subgroups (phenotypes), when the number
of subgroups and other information about their compo-
s i t i o nm a yb eu n k n o w n .W eh y p o t h e s i s e dt h a tF E NO
measurement could be associated with one of these
subgroups of asthmatic children. First, variables for the
cluster analysis were selected using a principal compo-
nent analysis (PCA). When considering variable selec-
tion for the cluster analysis, our aims were (1) to choose
variables that were measured in clinical practice and
contributed to the clinical evaluation of asthma, and to
avoid choosing different variables that were representa-
tive of the same aspect of the disease as this would
introduce further bias when the cluster analysis was per-
formed. We thus performed PCA of our 28 commonly
measured clinical variables. Orthogonal varimax rotation
was performed and the results are summarized in table
2. To avoid weighting the analysis, we selected only one
parameter that was representative of each factor. Two
additional variables were also included (see Table 2
legend). Then, a uniform cluster analysis methodology
was applied accordingly to Haldar and colleagues
(dendrogram for estimation of the number of likely clus-
ters that was further prespecified in a k-means cluster
analysis)[22]. Finally, characteristics of clusters were
compared using analysis of variance for continuous vari-
ables or Kruskal Wallis Rank test (non normal values)
and c2 test for proportions. Statistical analyses were
performed using MedCalc 11.3.8 (Mariakerke, Belgium)
and OpenStat (version 5) softwares.
Results
Between December 1, 2008 and April 14, 2010, 1001
NO measurements were performed in 592 asthmatic
children (clinical diagnose) of which 398 had a positive
bronchodilator response in their history. Of these 398
subjects, 169 met the criteria for inclusion in the cluster
analysis (all the children fulfilling inclusion criteria were
included). Non inclusion criteria were the absence of
recent skin pricks test (n = 62), the absence of broncho-
dilator test on the day of visit (absence of treatment
withdrawal, n = 130) and miscellaneous (n = 37). Table
1 shows the characteristics of the 169 asthmatic
children.
First approach
In univariate analysis, FENO was more elevated in atopic
than in non atopic children (35[19-57] pbb versus 12
[9-16] ppb, p < 0.001), less elevated in controlled chil-
dren (20 [13 - 37] ppb versus 34 [16-57] ppb, p = 0.018)
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(19 [13-34] versus 31 [16-57], p = 0.031). FENO corre-
lated with height (r = 0.29, p < 0.001), age (r = 0.25, p =
0.001), FEV1 (r = 0.18, p = 0.021) and bronchodilator
response (r = 0.26, p < 0.001). FENO was not decreased
by tobacco exposure in univariate analysis. The multi-
variate analysis demonstrated that 4 variables indepen-
dently correlated with log FENO (model: r = 0.60, p <
0.001): atopy (r = 0.46, p < 0.001), height (r = 0.29 p <
0.001), bronchodilator response (r = 0.26, p = 0.011)
and ICS dose > 200 μg/d (r = - 0.17, p = 0.019). Age,
control and forced expiratory flows did not indepen-
dently contribute to FENO variance.
Second approach
Orthogonal varimax rotation was performed and the
results are summarized in table 2. Based on the pattern
of loading we identified the factors as being representa-
tive of:
Factor 1: airway obstruction due to increased airway
tonus (and airway to lung size ratio)
Factor 2: anthropometrics
Table 2 Orthogonal varimax rotation results
28 variables factors
123 456 789
Clinical
gender - 0.765
age - 0.879
height - 0.889
weight - 0.905
BMI - 0.751
early wheezing (< 2 years) - 0.339 0.565 - 0.368
atopy (positive SPT) 0.800
parental smoking 0.764
Treatment
LABA 0.840
ICS treatment 0.872
ICS dose 0.898
ICS dose > 200 μg/d 0.814
Clinical events
partially or uncontrolled 0.439 0.626
days with symptoms 0.089 0.777
exacerbation 0.942 0.054
days with oral steroid 0.940 0.085
Baseline PFT values
FEV1 0.843
FEV1/FVC 0.843
sRaw - 0.609
RV/TLC 0.645 0.454
FEF50%/TLC 0.834 - 0.050
Post bronchodilator PFT values
FEV1 0.885
FEV1/FVC 0.757
sRaw - 0.391
RV/TLC 0.664
FEF50%/TLC 0.797 0.286
FEV1 response to BD % - 0.569 0.397 0.392
Exhaled NO - 0.061 - 0.132 - 0.119 - 0.059 0.789 - 0.149 0.064 0.030 0.076
PFT: denotes pulmonary function tests
All results for exhaled NO are shown in italic for information.
Factor analysis (PCA in our study) is based on the procedure for obtaining a new set of uncorrelated (orthogonal) variables, usually fewer in number than the
original set (9 instead of 28 in our study), that reproduces the co-variability observed among a set or original variables. Then we requested a rotation of the
resulting factors which follows completion of the analysis of the data. The most common rotation performed is the Varimax rotation[23]. This tends to produce
“simple structure”, that is, factors which have very high (that are provided in the table) or very low (provided for exhaled NO) loadings for the original variables
and thus simplifies the interpretation of the resulting factors.
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Factor 4: severe exacerbation
Factor 5: atopy
Factor 6: FEV1 (airway remodeling)
Factor 7: symptoms
Factor 8: gender
Factor 9: tobacco smoke exposure
Communality of all variables was > 60% (excepting
sRaw) and 74.8% of the total variance was explained by
the factors (all factors had Eigenvalues > 1). The Kaiser-
Meyer-Olkin measure of sampling adequacy was 0.643.
From this result we determined the 9 variables
selected for cluster analyses (we favored continuous
variables): gender, height, parental smoking, ICS dose,
number of days with symptoms and requiring oral
steroid, FEV1/FVC, FEV1 post BD and exhaled NO. Two
additional variables were selected (1) FEF50% /TLC post-
BD (index of airway/lung size) and (2) bronchodilator
response (index of airway tonus).
A four-cluster model best fitted the population data-
set, which were the following (Table 3): Cluster 1 (47%)
described a subgroup of asthmatic boys, unexposed to
tobacco, with well-controlled asthma, Cluster 2 (26%)
described a subgroup of girls, unexposed to tobacco,
with well-controlled asthma (similar to Cluster 1,
excepting gender), Cluster 3 (6%) described a subgroup
of girls or boys, unexposed to tobacco, with uncon-
trolled asthma associated with increased airway tone,
and Cluster 4 (21%) also described a subgroup of girls
or boys, exposed to parental smoking (either father,
mother or both), with small airway to lung size ratio
and uncontrolled asthma. The only difference (related to
gender) between Cluster 1 and 2 was their airway to
lung size ratio (p = 0.016, Fisher test).
Discussion
The main results of our study is the demonstration that
single-flow rate exhaled NO (FENO0.05) is independently
associated with two main asthma pathophysiological
characteristics, namely airway inflammation and airway
tone, but that FENO0.05 does not help to distinguish
a relevant clinical phenotype of childhood asthma in a
cross-sectional assessment.
Design issues
We specifically assessed different components of asthma
control definition, such as symptoms and exacerbations
because whether severe exacerbation constitutes the
ultimate expression of loss of control and/or a more
unpredictable even remains controversial[12,14]. Table 2
further showed that control and exacerbations were
two different dimensions of asthma, which could be
related to our pediatric population[14]. Only two levels
of control were assessed (controlled versus partially/
uncontrolled patients) because the achievement of
control is the main clinical issue. Our percentage of
controlled children (33%) is in accordance with a French
cross-sectional study in childhood asthma[26]. Since a
dose effect of ICS on exhaled NO can be demonstrated,
[2] we used it as an indirect index of airway inflamma-
tion, which is an obvious short-cut inasmuch as the
explained variance of FENO by ICS is only ~3% in our
study. Sputum eosinophilia can be regarded as the gold
standard measure of inflammation but is not routinely
assessed in most centres. The recent study of Schleich
and colleagues demonstrates that FENO is able to iden-
tify a sputum eosinophil count ≥ 3% with reasonable
accuracy and thresholds which vary according to dose of
ICS[27]. Finally, we deliberately chose to add two vari-
ables in the cluster analyses, namely post-bronchodilator
FEF50% /TLC and bronchodilator response. The former
is an index of airway size/lung size[28]. We hypothe-
sized that such an index, which has been linked to the
risk of airway responsiveness,[29] may influence
symptoms. The latter may also be an important patho-
physiological characteristico fa s t h m aa s s o c i a t e dw i t h
poor clinical outcomes in childhood asthma[30].
Four clusters were identified in our pediatric popula-
tion. The first two clusters can be considered similar
when excluding gender and corresponds to the most
prevalent group of asthmatic children in an out-hospital
specialized clinic (73%, 123/169) with 75/123 children
having partially/uncontrolled asthma. The remaining
two clusters (27%, 46/169) were constituted of boys and
girls with a more severe (or undertreated) disease (38/46
with partially/uncontrolled asthma, 20/46 with a recent
exacerbation). Interestingly, these two clusters only dif-
fer by their underlying severity factors, namely increased
airway tonus (cluster 3, 6% of the population) and par-
ental tobacco exposure while having small airway/lung
size ratio (cluster 4, 21%). The prevalence of cluster 3 is
similar to that of difficult-to-treat patients (~5%), and
m a ya l s oc o n s t i t u t ea na s t h m ap h e n o t y p ec h a r a c t e r i z e d
by increased airway tone and lability[14,30]. The fourth
cluster segregates children exposed to passive smoking
that have a more severe disease, which is in line with
the results of a French cross-sectional study in 3431
children demonstrating that unacceptable asthma con-
trol was associated with passive exposure to parental
tobacco smoke[26]. Overall, the phenotypes that have
been identified by the cluster analysis can be a posteriori
explained, which further validate the statistical approach
to assess exhaled NO usefulness. It has to be empha-
sized that the degree of asthma control did not clearly
differentiate the clusters in our study. Several explana-
tions can be discussed. Firstly, our study deals with
childhood asthma, this specific population is often
partially controlled because some degree of exercise
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Characteristics Cluster 1
n=7 9
Cluster 2
n=4 4
Cluster 3
n=1 1
Cluster 4
n=3 5
P value*
Gender, girls/boys
# 0/79 44/0 5/6 16/19 < 0.001
Age, years 10.6 ± 2.9 11.0 ± 2.6 10.0 ± 1.3 10.0 ± 2.3 0.34
Height, cm
# 144 ± 17 143 ± 14 139 ± 9 139 ± 14 0.33
Weight, kg 39 ± 16 38 ± 16 35 ± 7 35 ± 13 0.46
BMI, kg.m
-2 18.2 ± 3.2 18.0 ± 4.2 17.8 ± 2.3 17.7 ± 3.4 0.92
Early wheezing, n 33 19 4 12 0.86
Atopy, n (%) 67 (85) 39 (89) 8 (73) 28 (80) 0.55
Tobacco exposure, both
# 0 0 1 35 < 0.001
maternal 0 0 0 25 < 0.001
paternal 0 0 1 23 < 0.001
ICS, n (%) 37 (47) 25 (57) 5 (45) 20 (57) 0.62
ICS dose, BED μg/d
# 135 ± 208 180 ± 236 149 ± 199 188 ± 217 0.57
LABA, n 33 (42) 22 (50) 4 (36) 15 (43) 0.58
Clinical events
Partially or uncontrolled, n 46 (58) 29 (66) 10 (91) 28 (80) 0.028
Days with symptoms
# 3 [0-8] 4 [0-12] 3 [3-7] 7 [3-15] 0.045
With exacerbation, n 16 (20) 6 (14) 6 (55) 14 (41) 0.006
Days with oral steroid
# 0 [0-0] 0 [0-0] 3 [0-3] 0 [0-3] 0.021
Pulmonary function tests
Before bronchodilation
FENO, ppb
# 25 [14-45] 34 [19-51] 21 [9-49] 30 [14-52] 0.58
sRaw, % pred 201 ± 40 200 ± 54 211 ± 37 212 ± 47 0.68
FEF50%/TLC 0.70 ± 0.13 0.74 ± 0.13 0.62 ± 0.15 0.69 ± 0.14 0.5
FEV1, % pred 98 ± 13 100 ± 13 91 ± 14 97 ± 14 0.28
FVC, % pred 104 ± 14 106 ± 13 106 ± 15 106 ± 12 0.88
FEV1/FVC
# 78 ± 8 80 ± 6 74 ± 8 77 ± 9 0.41
FEF25-75%, % pred 74 ± 18 72 ± 18 59 ± 19 70 ± 20 0.1
TLC, % pred 105 ± 12 104 ± 9 103 ± 12 106 ± 10 0.32
FRC, % pred 103 ± 17 102 ± 17 101 ± 22 105 ± 18 0.22
RV, % pred 107 ± 28 104 ± 27 101 ± 20 115 ± 32 0.23
RV/TLC 0.24 ± 0.06 0.25 ± 0.06 0.24 ± 0.04 0.27 ± 0.06 0.14
After bronchodilation
sRaw, % pred 125 ± 28 127 ± 31 117 ± 22 133 ± 34 0.22
FEF50%/TLC
# 0.78 ± 0.17 0.86 ± 0.15 0.80 ± 0.22 0.75 ± 0.22 0.025
FEV1, % pred
# 107 ± 12 110 ± 12 105 ± 14 107 ± 12 0.47
FVC, % pred 107 ± 13 108 ± 12 107 ± 14 110 ± 12 0.69
FEV1/FVC, % 84 ± 6 86 ± 4 83 ± 8 82 ± 7 0.05
FEF25-75%, % pred 92 ± 20 95 ± 16 86 ± 25 84 ± 21 0.17
TLC, % pred 103 ± 11 102 ± 9 101 ± 13 104 ± 10 0.73
FRC, % pred 101 ± 16 100 ± 14 95 ± 19 101 ± 13 0.3
RV, % pred 95 ± 22 90 ± 22 91 ± 25 96 ± 23 0.78
RV/TLC 0.22 ± 0.05 0.22 ± 0.05 0.23 ± 0.04 0.23 ± 0.05 0.6
Bronchodilator response, %
# 8 [5-12] 10 [5-17] 15 [9-20] 8 [3-16] 0.036
# : variables included in the cluster analysis
* : Comparison between clusters using analysis of variance for continuous variables or Kruskal Wallis Rank test (non normal values) and c
2 test for proportions.
Significance values for variables included in the cluster analysis are a product of the cluster algorithm and are provided for illustrative purposes only.
Results are provided as mean ± SD or median [25
th -7 5
th percentiles] or absolute number with percent age (%).
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tions are often unpredictable events, mostly related to
viral infections [31,32]. Secondly, normal lung function
(under treatment) is the rule in asthmatic children
[15,17] and a « phenotype » of children exhibiting a
decline in lung function is almost impossible to isolate
[17]. Thirdly, therapeutic compliance (and inability to
use the inhaler properly) in children may be difficult to
obtain [33] that may further explain the presence of
mild symptoms.
Usefulness of FENO0.05 measurement
We confirm by our first statistical approach that FENO is
linked to its classical modifiers such as height and atopy.
The link with ICS dose is more controversial, but we
previously evidenced such a link with a plateau effect of
ICS[6]. We show that exhaled NO and bronchodilator
response are linked, a result that was previously
obtained by different research groups[2,3,9]. More
interestingly, we demonstrate for the first time that the
relationships between exhaled NO and both ICS dose (an
indirect marker of airway inflammation) and bronchodi-
l a t o rr e s p o n s e( am a r k e ro fa i r w a yt o n u s )a r ei n d e p e n -
dent. Exhaled NO measurement is claimed to be an
allergic inflammometer, but it is also a marker of airway
smooth muscle tone[34].
The recent study of Dweik and colleagues has shown
that a high FENO “phenotype” (FENO 0.05 > 35 ppb) was
characterized by greatest airway reactivity, airflow lim-
itation, hyperinflation, sputum eosinophilia and levels of
symptoms[9]. Consequently, our results (first statistical
approach) are in agreement with their data, but we
further suggest that FENO is not specifically associated
with a clinically relevant phenotype in asthmatic chil-
dren. Haldar and colleagues elegantly demonstrated that
eosinophilic inflammation helps to characterize adult
asthma phenotypes[22]. Consequently our results may
seem at variance, but exhaled NO and airway eosinophi-
lia could be discordant in childhood[14]. In summary, to
our best knowledge, this is the first study in childhood
asthma, showing that exhaled NO does help to describe
ac l i n i c a l l yu s e f u lp h e n o t y p ed e s p i t ei t sa b i l i t yt o
describe underlying pathophysiology (inflammation and
modified airway smooth muscle function).
Limitations of the study
Principal among these is the cluster analysis methodol-
ogy. The use of an algorithm that separates the popula-
tion into discrete clusters may not be realistic. The
limited size of our out-hospital population, the restricted
analysis of childhood asthma (that could be a more
homogeneous disease per se), our choice of clustering
parameters and the loss of clinical material through
attrition of the data set may have introduced some bias,
b u tw eh y p o t h e s i z e dt h a tt h ec l i n i c a lr e l e v a n c eo f
exhaled NO should be “easily” demonstrated. It has to
be stated that, in a cross-sectional design mainly asses-
sing asthma control, FENO0.05 was not associated with
a specific cluster, which is in accordance with recent
trials failing to demonstrate the clinical usefulness of
this measure for asthma control[35].
Perspectives
It has to be emphasized that, in a cross-sectional design
mainly assessing asthma control, FENO0.05 was not
associated with a specific cluster, which is in accordance
with recent trials failing to demonstrate the clinical
usefulness of this measure for asthma control[35].
Whether peripheral airway/alveolar NO concentration
after correction for axial NO back-diffusion, which is
elevated in a subset of asthmatic patients (~25%), could
help to identify a specific “phenotype” of asthma war-
rants further studies[4,36,37].
In conclusion, FENO0.05 is independently linked to two
pathophysiological characteristics of childhood asthma
(ICS-dependant inflammation and bronchomotor tone)
but does not help to identify a clinically relevant pheno-
type of asthmatic children in a cross-sectional analysis of
routinely recorded parameters.
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